Blog Layout

Forthcoming Changes in NCI's Clinical Trials Program

The Cooperative Groups


The major clinical trials enterprise in the United States, called the Clinical Trials Cooperative Group Program, has grown, but its design has remained largely unchanged for 55 years. Recognizing that our clinical trials must keep pace with advances in the scientific understanding of cancer, the Institute of Medicine (IOM) issued a report Exit Disclaimer at NCI’s request in 2010 that outlined necessary, systematic changes to more efficiently design, review, and conduct studies.


In keeping with the recommendations outlined in the IOM report and with the advice of clinical scientists from across the country, NCI has created a new National Clinical Trials Network (NCTN). The NCTN will improve the speed and efficiency of cancer clinical trials, using fewer but larger groups of investigators and distributing resources in a more effective way. In addition to supporting the new network’s clinical trial groups with awards for operations and statistical analysis, the NCTN provides funding for a centralized Institutional Review Board (IRB); for correlative studies (through the Biomarker, Imaging, and Quality-of-Life Studies Funding Program); for new awards created specifically for the NCTN, including Lead Academic Participating Site (LAPS) grants and Integrated Translational Science Awards (ITSA); and for additional contracts to support the infrastructure of the network (e.g., pharmacy services and regulatory support). 


Despite the current budget environment in which NCI is operating—at levels of appropriated funds below those of FY2010—our monetary support for clinical trials remains strong. In FY2013, NCI singled out its national clinical trials program as an area that would not incur any budget reductions, despite sequestration. This year (FY2014), funding levels for clinical trials are unchanged from FY2013. 


The formal awards for the NCTN are expected to be made in the coming weeks. The capacity of the NCTN to conduct clinical trials will reflect the difficulties of supporting a large program that is constrained by higher mandatory costs and by the rate of biomedical inflation, despite approximately constant dollars. The number of trials that can be funded and the network’s total enrollment (estimated to be about 17,000 patients in interventional trials and about 2,500 patients in trials that use molecular markers to screen for tumors) will be lower than in the past. These operational concessions are required to provide higher reimbursement rates per patient to the academic sites that are developing and performing trials, as recommended by the IOM report. (These higher rates will be approximately $4,000 per patient for about 50 percent of the patients accrued through the network accrual, compared with approximately $2,000 previously.)   


Community-based Clinical Trials


NCI also has a decades-long commitment to clinical cancer research in the community, where most cancer patients are treated and followed. Through programs such as the Community Clinical Oncology Program (CCOPs), the Minority-based Community Clinical Oncology Program (MCCOPs), and the NCI Community Cancer Centers Program (NCCCP), NCI has developed and maintained the availability of state-of-the-art clinical research throughout the United States.


The value of community-based practices for providing access to clinical trials is fundamental to testing promising new interventions in settings in which most patients are seen. Because advances in oncology are occurring rapidly, community-based care must also adapt swiftly, requiring changes in the manner in which clinical trials are conducted in the community. Therefore, NCI is consolidating its several existing community-based programs into an NCI Community Oncology Research Program (NCORP), in a way that enables community-based programs to benefit from intellectual and operational resources available through the NCTN. 


NCORP is designed to become an integral component of the overall NCI NCTN. It will provide access to studies of cancer control, prevention, screening, treatment, and cancer care delivery in the communities in which individuals live. NCORP will be comprised of some of the sites formerly funded through the CCOPs, MCCOPs, and NCCCP, as well new grantee institutions, in accord with advice received from many sectors during the planning process.


During the transition to NCORP, we expect to announce most awards before the planned September 2014 date, avoiding disruption in existing community-based sites that successfully compete for NCORP awards. Existing sites that are not successful in the competition for NCORP awards will receive funds needed to ensure a smooth closeout of operations. In accord with traditional NCI practice, no patients will be removed from a trial as a result of the reorganization, and accrual into existing studies will continue. The NCI’s long-term goal remains the maintenance of a strong program for community-based clinical research.


For more information, please visit http://www.cancer.gov/newscenter/newsfromnci/2014/NCTNlaunch.

Share this Article with others

08 Mar, 2024
The aims of our case-control study were (1) to develop an automated 3-dimensional (3D) Convolutional Neural Network (CNN) for detection of pancreatic ductal adenocarcinoma (PDA) on diagnostic computed tomography scans (CTs), (2) evaluate its generalizability on multi-institutional public data sets, (3) its utility as a potential screening tool using a simulated cohort with high pretest probability, and (4) its ability to detect visually occult preinvasive cancer on prediagnostic CTs.
08 Mar, 2024
Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
08 Mar, 2024
International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer.
08 Mar, 2024
The majority of disease-associated variants identified through genome-wide association studies are located outside of protein-coding regions. Prioritizing candidate regulatory variants and gene targets to identify potential biological mechanisms for further functional experiments can be challenging. To address this challenge, we developed FORGEdb, a standalone and web-based tool that integrates multiple datasets, delivering information on associated regulatory elements, transcription factor binding sites, and target genes for over 37 million variants. FORGEdb scores provide researchers with a quantitative assessment of the relative importance of each variant for targeted functional experiments.
By Bo Zhang 08 Mar, 2024
Cancer is a leading cause of morbidity and mortality worldwide. While progress has been made in the diagnosis, prognosis, and treatment of cancer patients, individualized and data-driven care remains a challenge. Artificial intelligence (AI), which is used to predict and automate many cancers, has emerged as a promising option for improving healthcare accuracy and patient outcomes. AI applications in oncology include risk assessment, early diagnosis, patient prognosis estimation, and treatment selection based on deep knowledge. Machine learning (ML), a subset of AI that enables computers to learn from training data, has been highly effective at predicting various types of cancer, including breast, brain, lung, liver, and prostate cancer. In fact, AI and ML have demonstrated greater accuracy in predicting cancer than clinicians. These technologies also have the potential to improve the diagnosis, prognosis, and quality of life of patients with various illnesses, not just cancer. Therefore, it is important to improve current AI and ML technologies and to develop new programs to benefit patients. This article examines the use of AI and ML algorithms in cancer prediction, including their current applications, limitations, and future prospects. Lead Author: Bo Zhang
By Claudio Luchini 08 Mar, 2024
Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology. First Author: Claudio Luchini,
By Panayiotis Petousis, PhD 08 Mar, 2024
In the United States, end-stage kidney disease (ESKD) is responsible for high mortality and significant healthcare costs, with the number of cases sharply increasing in the past 2 decades. In this study, we aimed to reduce these impacts by developing an ESKD model for predicting its occurrence in a 2-year period.  Lead Author: Panayiotis Petousis, PhD
By Evan D. Muse 08 Mar, 2024
Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management Lead Author: Evan D. Muse
By Danielle S. Bitterman, MD 08 Mar, 2024
Current status and future applications of LLMs for cancer symptom management and call for cross-disciplinary collaboration that centers the needs of patients and caregivers L ead Author: Danielle S. Bitterman, MD
01 Mar, 2023
New computer systems aim to peer inside our heads—and to help us fix what they find there In the nineteen-sixties, Joseph Weizenbaum, a computer scientist at M.I.T., created a computer program called Eliza. It was designed to simulate Rogerian therapy, in which the patient directs the conversation and the therapist often repeats her language back to her: U ser : My boyfriend made me come here. E liza : Your boyfriend made you come here. U ser : He says I’m depressed much of the time. E liza : I am sorry to hear you are depressed. U ser : It’s true. I am unhappy. E liza : Do you think coming here will help you not to be unhappy? Weizenbaum made Eliza as satire. He doubted that computers could simulate meaningful human interaction. He was alarmed, therefore, when many people who tried the program found it both useful and captivating. His own secretary asked him to leave the room so that she could spend time alone with Eliza. Worse, doctors saw it as a potentially transformative tool. “Several hundred patients an hour could be handled by a computer system designed for this purpose,” three psychiatrists wrote in The Journal of Nervous and Mental Disease, in 1966. “The human therapist, involved in the design and operation of this system, would not be replaced, but would become a much more efficient man since his efforts would no longer be limited to the one-to-one patient-therapist ratio as now exists.” Weizenbaum became an outspoken critic of artificial intelligence. “But the genie was out of the bottle,” Brian Christian, who chronicled the episode in his book “The Most Human Human,” told me. A few years later, a Stanford psychiatrist named Kenneth Colby created Parry, a program that attempted to simulate the language of a person with paranoid schizophrenia, to train students before they cared for real patients. Psychiatrists given transcripts of therapy sessions often couldn’t tell the difference between Parry and humans; in this narrow sense, the chatbot passed the Turing test. In 1972, Parry and Eliza met up for a therapy session: P arry : Do you know anything about bookies? E liza : What makes you think I know anything about bookies? P arry : A bookie didn’t pay me off once. E liza : What does that suggest to you? P arry : I beat up the bookie who did not pay off, and I thought he might use his friends in the underworld to get even with me.  Over time, programmers developed Jabberwacky, Dr. Sbaitso, and alice (the Artificial Linguistic Internet Computer Entity). Exchanges with these chatbots were often engaging, sometimes comical, and occasionally nonsensical. But the idea that computers could serve as human confidants, expanding therapy’s reach beyond the limits of its overworked practitioners, persisted through the decades. In 2017, Alison Darcy, a clinical research psychologist at Stanford, founded Woebot, a company that provides automated mental-health support through a smartphone app. Its approach is based on cognitive behavioral therapy, or C.B.T.—a treatment that aims to change patterns in people’s thinking. The app uses a form of artificial intelligence called natural language processing to interpret what users say, guiding them through sequences of pre-written responses that spur them to consider how their minds could work differently. When Darcy was in graduate school, she treated dozens of hospitalized patients using C.B.T.; many experienced striking improvements but relapsed after they left the hospital. C.B.T. is “best done in small quantities over and over and over again,” she told me. In the analog world, that sort of consistent, ongoing care is hard to find: more than half of U.S. counties don’t have a single psychiatrist, and, last year, a survey conducted by the American Psychological Association found that sixty per cent of mental-health practitioners don’t have openings for new patients. “No therapist can be there with you all day, every day,” Darcy said. Although the company employs only about a hundred people, it has counseled nearly a million and a half, the majority of whom live in areas with a shortage of mental-health providers. Link to original article on The New Yorker
Share by: